Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Actinium Pharmaceuticals Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • Celator Pharmaceuticals
  • Echo Therapeutics Inc.
  • FluoroPharma Medical Inc.
  • Incyte Corp.
  • Merck & Co. Inc.
  • Merrimack Pharmaceuticals Inc.
  • Navidea Biopharmaceuticals Inc.
  • Roche Holding AG
  • StemCells Inc.
  • Sunesis Pharmaceuticals Inc.

Stephen Dunn

LifeTech Capital

Image: Stephen Dunn

LifeTech Capital President and Senior Managing Director Stephen Dunn was previously the managing director of Life Sciences Research at Jesup & Lamont, as well as director of research for Dawson James Securities and director of Life Sciences at Cabot Adams venture capital group. He has held management positions in business development, finance and operations, having worked in more than 25 countries in North America, Europe and the Far East with biomedical companies including Beckman Coulter, Coulter, Cordis (Johnson & Johnson) and Telectronics (St. Jude Medical), as well as several smaller companies. With more than 25 years in the global biomedical industry, Dunn has negotiated numerous intellectual property licenses, product development agreements, venture funding, mergers and acquisitions and joint ventures. Dunn is a five-star biotechnology analyst on StarMine and has appeared in both the financial and scientific media, including The Wall Street Journal, CNN, Newsweek, Forbes, Nightly Business Report, Nature Biotechnology, The Scientist, BioWorld and many other media outlets. He is a frequent speaker and panel member for many financial, medical and venture capital events.




Recent Interviews

ASCO Abuzz About Immunotherapies: A Preview of the Latest in Cancer Therapy from Stephen Dunn (5/28/14) Working in what is arguably the hottest sector in the drug development industry, biotech researchers continue to ferret out cancer's secrets. The premier event for those in the field is the American Society of Clinical Oncology annual meeting, taking place in Chicago from May 30 to June 1. Participants have submitted abstracts for promising therapies in advance of the conference, profiling new compounds that could lead to better outcomes for patients and bolster the health of investment portfolios. In this interview with The Life Sciences Report, LifeTech Capital's Stephen Dunn walks us through some of the highlights.

Can Stem Cells Regenerate Your Portfolio? Stephen Dunn Says Yes (9/27/12) Once the subject of intense political debate, stem cell therapies may soon be a therapeutic mainstay of healthcare. In this exclusive interview with The Life Sciences Report, LifeTech Capital's President and Senior Managing Director of Research Stephen Dunn explores the history of stem cell therapy and discusses companies that are reviving this "old" technique for profit.

Vaccine Therapies Hold Promise for Investors: Stephen Dunn (4/12/12) Developing vaccines to treat and/or prevent disease promises life-changing benefits for patients and unique opportunities for investors. In this interview with The Life Sciences Report, LifeTech Capital Senior Managing Director and President Stephen Dunn discusses the roadblocks encountered by some developers of immune therapies and how other companies are working around those obstacles, producing investment opportunities in the process.

Recent Quotes

"STEM continues to build on its strong management team." (7/7/14) StemCells Inc. - Stephen Dunn, LifeTech Capital More >

"It appears that STEM's HuCNS-SC is disease modifying in dry AMD." (6/19/14) StemCells Inc. - Stephen Dunn, LifeTech Capital More >

"STEM adds to its executive team, one of the strongest in the space." (6/17/14) StemCells Inc. - Stephen Dunn, LifeTech Capital More >

"ATNM is developing Iomab-B for acute myeloid leukemia patients undergoing a bone marrow transplant." (5/28/14) Actinium Pharmaceuticals Inc. - The Life Sciences Report Interview with Stephen Dunn More >

"STEM's results on thoracic SCI patients are very significant." (5/20/14) StemCells Inc. - Stephen Dunn, LifeTech Capital More >

"STEM completed enrollment in its SCI Phase 1/2 clinical trial." (4/17/14) StemCells Inc. - Stephen Dunn, LifeTech Capital More >

"STEM remains one of the most advanced players in the stem cell space." (3/24/14) StemCells Inc. - Stephen Dunn, LifeTech Capital More >

"CIRM's $19M funding for HuCNS-SC in Alzheimer's disease validates STEM's research." (1/10/14) StemCells Inc. - Stephen Dunn, LifeTech Capital More >

more comments

"STEM's strong management team and strong science continues to be successfully validated." (1/2/14) StemCells Inc. - Stephen Dunn, LifeTech Capital More >

"For investors with a long time horizon, CUR could be very rewarding." (9/27/12) Neuralstem Inc. - The Life Sciences Report Interview with Stephen Dunn More >

fewer comments


Due to permission requirements, not all quotes are shown.